We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Diabetes

Journal Scan / Research · August 22, 2018

Efficacy and Safety of Semaglutide Compared With Liraglutide and Placebo for Weight Loss in Patients With Obesity

The Lancet

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Efficacy and Safety of Semaglutide Compared With Liraglutide and Placebo for Weight Loss in Patients With Obesity: A Randomised, Double-Blind, Placebo and Active Controlled, Dose-Ranging, Phase 2 Trial
Lancet 2018 Aug 16;[EPub Ahead of Print], PM O'Neil, AL Birkenfeld, B McGowan, O Mosenzon, SD Pedersen, S Wharton, CG Carson, CH Jepsen, M Kabisch, JPH Wilding

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading